Human organoids for Risk Group 4 virus research: a new frontier in investigating Nipah virus infection of the central nervous system

用于风险组 4 病毒研究的人类类器官:研究尼帕病毒感染中枢神经系统的新前沿

阅读:14
作者:Gabriella Worwa ,Shuǐqìng Yú ,Amanda M W Hischak ,Julie P Tran ,Jeremy J Bearss ,John Bernbaum ,Daniel B Woodburn ,Bapi Pahar ,Jillian Geiger ,Louis M Huzella ,Santiago Vidal Freire ,Ian Crozier ,César Muñoz-Fontela ,Gustavo Palacios ,Nicole C Kleinstreuer ,Lina Widerspick ,Jens H Kuhn

Abstract

New approach methodologies, such as high-complexity in vitro systems, are increasingly prioritized in biomedical research as potential alternatives to animal experimentation. We show that cerebral organoids derived from human induced pluripotent stem cells can be leveraged to (i) investigate isolate-specific replication dynamics of Nipah virus and (ii) model key histopathological lesions found in the brain tissue of infected human patients. Furthermore, we discuss the importance of organoid models for the study of Risk Group 4 viruses. Importance: Advanced development of medical countermeasures against Risk Group 4 viruses, such as the Nipah virus, historically required testing in mammals under the FDA Animal Rule and translation of data to inform clinical trials in humans. Because the application of human organoids in research on viruses pathogenic for humans is conspecific, it bears the potential to reduce, refine, or replace animal studies where unnecessary. Human cerebral organoids are three-dimensional cell aggregates that resemble the developing human brain functionally and structurally. Brain organoids may be valuable in investigating the replication, neuroinvasion, pathogenesis, virulence, and persistence of neurotropic viruses and provide scientific discernment when developing medical countermeasures destined for the human end-user.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。